Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Net Income towards Common Stockholders (2016 - 2025)

iBio (IBIO) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with -$9.0 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 106.07% to -$9.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.7 million through Dec 2025, down 83.93% year-over-year, with the annual reading at -$18.4 million for FY2025, 94.18% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$9.0 million at iBio, down from -$5.7 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $51000.0 in Q2 2021, with the low at -$23.0 million in Q4 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$6.5 million, with a median of -$5.0 million recorded in 2025.
  • The sharpest move saw Net Income towards Common Stockholders surged 101.42% in 2021, then plummeted 33539.22% in 2022.
  • Over 5 years, Net Income towards Common Stockholders stood at -$11.9 million in 2021, then tumbled by 92.51% to -$23.0 million in 2022, then soared by 83.81% to -$3.7 million in 2023, then fell by 17.22% to -$4.4 million in 2024, then crashed by 106.07% to -$9.0 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$9.0 million, -$5.7 million, and -$5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.